SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    De Vita S, de Re V, Gasparotto D, Ballare M, Pivetta B, Ferraccioli G, et al. Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: clinical and molecular findings do not support a bone marrow pathologic diagnosis of indolent B cell lymphoma. Arthritis Rheum 2000; 43: 94102.
  • 2
    Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC, et al, for the MULTIVIRC Group. Extrahepatic manifestations of chronic hepatitis C. Arthritis Rheum 1999; 42: 220412.
  • 3
    Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327: 14905.
  • 4
    Casato M, Agnello V, Pucillo LP, Knight GB, Leoni M, del Vecchio S, et al. Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 1997; 90: 386573.
  • 5
    Dammacco F, Sansonno D, Han JH, Shyamala V, Cornacchiulo V, Iacobelli AR, et al. Natural interferon-α versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 1994; 84: 333643.
  • 6
    Ferri C, Marzo E, Longombardo G, Lombardini F, la Civita L, Vanacore R, et al. Interferon-α in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood 1993; 81: 11326.
  • 7
    Misiani R, Bellavita P, Fenili D, Vicari O, Marchesi D, Sironi PL, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994; 330: 7516.
  • 8
    Cacoub P, Lidove O, Maisonobe T, Duhaut P, Thibault V, Ghillani P, et al. Interferon-α and ribavirin treatment in patients with hepatitis C virus–related systemic vasculitis. Arthritis Rheum 2002; 46: 331726.
  • 9
    Zuckerman E, Keren D, Slobodin G, Rosner I, Rozenbaum M, Toubi E, et al. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-α. J Rheumatol 2000; 27: 21728.
  • 10
    Sansonno D, de Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon α with an anti-CD20. Blood 2003; 101: 381826.
  • 11
    Zaja F, de Vita S, Mazzaro C, Sacco S, Damiani D, de Marchi G, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101: 382734.
  • 12
    Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, et al, and the Hepatitis C Intervention Therapy Group. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000; 68: 55667.
  • 13
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 97582.
  • 14
    The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 1520.
  • 15
    Naarendorp M, Kallemuchikkal U, Nuovo GJ, Gorevic PD. Longterm efficacy of interferon-α for extrahepatic disease associated with hepatitis C virus infection. J Rheumatol 2001; 28: 246673.